Roche buys into Prothena... kind of

Roche buys into Prothena... kind of

Source: 
EP Vantage
snippet: 

Perhaps the fact that Roche has not scrapped development of its Prothena-partnered Parkinson’s disease project prasinezumab is good news in itself. This and the Swiss group committing to pay Prothena $60m on the initiation of the asset’s next study has sent up the smaller company’s shares 7% this morning.